Vanda Pharmaceuticals Q4 Earnings Call Highlights

Core Insights - Vanda Pharmaceuticals reported a 9% increase in total revenues for 2025, reaching $216.1 million, primarily driven by growth in Fanapt sales, despite a decline in Hetlioz revenue due to generic competition [2][4] Financial Performance - Full-year net product sales for Hetlioz decreased by 7% to $71.4 million, attributed to lower volume and pricing pressures from U.S. generic competition [1] - Fanapt net product sales increased by 24% to $117.3 million, supported by a 28% rise in total prescriptions and a 149% increase in new-to-brand prescriptions [3] - The company reported a full-year net loss of $220.5 million for 2025, significantly higher than the $18.9 million loss in 2024, largely due to a one-time, non-cash tax charge [5][7] Quarterly Performance - Fourth-quarter total revenues were $57.2 million, an 8% year-over-year increase, with Fanapt sales rising by 25% to $33.2 million [6] - Hetlioz's fourth-quarter net product sales fell by 18% to $16.4 million, while Ponvory's sales increased by 17% to $7.6 million [7] Operating Expenses - Operating expenses rose to $367.3 million in 2025 from $239.4 million in 2024, driven by increased SG&A expenses related to commercial launches and higher R&D costs [8] Cash Position - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $263.8 million, down $110.8 million from the previous year [9] Pipeline and Regulatory Updates - The FDA approved Nereus for motion-induced vomiting, marking a significant regulatory achievement for the company [11] - Vanda plans to initiate a phase III program for tradipitant in vomiting associated with GLP-1 agonists in the first half of 2026 [12] - The NDA for Bysanti is under FDA review with a PDUFA date of February 21, 2026 [13] - The company submitted the BLA for imsidolimab for generalized pustular psoriasis in Q4 2025 [14] Commercial Strategy - Vanda expanded its commercial infrastructure, increasing the Fanapt sales force from about 160 to 300 representatives by the end of 2025 [15] - For 2026, the company expects total revenues from currently marketed products to be between $230 million and $260 million, with a continued decline in Hetlioz sales anticipated [16] Future Guidance - The company does not provide cash guidance for 2026 but expects cash burn to exceed 2025 levels [17] - Vanda is also pursuing clinical development programs for Ponvory in psoriasis and ulcerative colitis, with ongoing studies for Bysanti and VQW-765 [19]